You are here
{Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group
Tuesday,2020-10-27 18:46 America/Los_Angeles — ecterry
| Title | {Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group |
| Publication Type | Journal Article |
| Year of Publication | 2019 |
| Authors | Irvin, MR, Sitlani, CM, Floyd, JS, Psaty, BM, Bis, JC, Wiggins, KL, Whitsel, EA, Sturmer, T, Stewart, J, Raffield, L, Sun, F, Liu, CT, Xu, H, Cupples, AL, Tanner, RM, Rossing, P, Smith, A, Zilh?o, NR, Launer, LJ, Noordam, R, Rotter, JI, Yao, J, Li, X, Guo, X, Limdi, N, Sundaresan, A, Lange, L, Correa, A, Stott, DJ, Ford, I, Jukema, JW, Gudnason, V, Mook-Kanamori, DO, Trompet, S, Palmas, W, Warren, HR, Hellwege, JN, Giri, A, O'Donnell, C, Hung, AM, Edwards, TL, Ahluwalia, TS, Arnett, DK, Avery, CL |
| Journal | Am J Hypertens |
| Volume | 32 |
| Pagination | 1146–1153 |
| Date Published | 11 |
| Abstract | {Only a handful of genetic discovery efforts in apparent treatment-resistant hypertension (aTRH) have been described.\ We conducted a case-control genome-wide association study of aTRH among persons treated for hypertension, using data from 10 cohorts of European ancestry (EA) and 5 cohorts of African ancestry (AA). Cases were treated with 3 different antihypertensive medication classes and had blood pressure (BP) above goal (systolic BP ≥ 140 mm Hg and/or diastolic BP ≥ 90 mm Hg) or 4 or more medication classes regardless of BP control (nEA = 931 |
ePub date:
19/09